- Service Name
Otezla® (apremilast)
- Industry
Pharmaceutical, healthcare, prescription medication, dermatology, rheumatology
- Main Value Proposition
Otezla® provides effective treatment for chronic conditions, improving patients' quality of life by addressing symptoms from within.
- Description
Otezla® is a prescription medication designed to treat various conditions such as plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It works from the inside out to provide relief from symptoms and improve the quality of life for patients.
- Key Features
Treats plaque psoriasis, psoriatic arthritis, and oral ulcers in Behçet’s Disease.; Works from the inside out.; Available for both adults and pediatric patients.; Offers a co-pay program that may allow eligible patients to pay as little as $0.
- Use Cases
Otezla® is most valuable for patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease, particularly those looking for an effective oral treatment option.
- Competitive advantages
Oral administration, making it easier for patients compared to injectable treatments.; A comprehensive co-pay program that reduces out-of-pocket costs for eligible patients.; A focus on treating multiple conditions with a single medication.
- Strengths
Otezla® is well-regarded for its efficacy in treating chronic skin and joint conditions, its ease of use as an oral medication, and its supportive patient programs.
- Positioning
Otezla® positions itself as a leading oral treatment option for chronic inflammatory conditions, emphasizing its unique mechanism of action and patient support.
- Audience
The target users include adults and pediatric patients with moderate to severe plaque psoriasis, adults with psoriatic arthritis, and adults with oral ulcers due to Behçet’s Disease.
- CTA
Sign Up for Info
- Tags
psoriasis
psoriatic arthritis
oral ulcers
chronic treatment
- Tagline
Live in the moment.
- Tone of Voice
Supportive, informative, empathetic
- Differentiation
Otezla® is unique in that it is the only oral medication that targets the underlying causes of psoriasis and psoriatic arthritis rather than just treating surface symptoms.
- Brand Positioning
Amgen, the manufacturer of Otezla®, positions the brand as a compassionate and innovative leader in the pharmaceutical industry, dedicated to improving patient outcomes.
- Founded
2014-03-21